A Single Center, Open-label, Phase II Clinical Trial to Evaluate the Efficacy and Safety of MG4101(Ex Vivo Expanded Allogeneic NK Cell) in Hepatocellular Carcinoma After Curative Resection
Phase of Trial: Phase II
Latest Information Update: 09 Dec 2015
Price : $35 *
At a glance
- Drugs MG 4101 (Primary)
- Indications Liver cancer
- Focus Therapeutic Use
- 31 Aug 2018 Biomarkers information updated
- 02 Dec 2015 Status changed from recruiting to completed as reported by ClinicalTrials.gov record.
- 22 Sep 2014 Planned End Date changed from 1 Dec 2015 to 1 Aug 2016 as reported by ClinicalTrials.gov.